当前蛋白身份：P78536
重新检索
差异标签只比较当前检索结果；所有PDB和assembly原始记录仍分别保留。
相关结构差异明细
一行代表一个 PDB 条目中的一个 biological assembly；同一蛋白的多个单体会分别列出。
| PDB 条目 | Assembly / 聚集状态 | 构建体 | 突变与修饰 | 配体、离子与非聚合物 | 实验方法 | 实验环境 | 结构质量 |
|---|---|---|---|---|---|---|---|
| 1BKC CATALYTIC DOMAIN OF TNF-ALPHA CONVERTING ENZYME (TACE) 提交 1998-04-23 | Assembly 1 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 A
219–474（256 aa）
|
突变：S266A, N452Q | ZN ZINC ION × 1 INN N-{(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}-3-methyl-L-valyl-N-(2-aminoethyl)-L-alaninamide × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
pH 5.4；pH 5.4
|
分辨率 2.00 Å R-free 0.270 |
| 1BKC CATALYTIC DOMAIN OF TNF-ALPHA CONVERTING ENZYME (TACE) 提交 1998-04-23 | Assembly 2 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 E
219–474（256 aa）
|
突变：S266A, N452Q | ZN ZINC ION × 1 INN N-{(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}-3-methyl-L-valyl-N-(2-aminoethyl)-L-alaninamide × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
pH 5.4；pH 5.4
|
分辨率 2.00 Å R-free 0.270 |
| 1BKC CATALYTIC DOMAIN OF TNF-ALPHA CONVERTING ENZYME (TACE) 提交 1998-04-23 | Assembly 3 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 C
219–474（256 aa）
|
突变：S266A, N452Q | ZN ZINC ION × 1 INN N-{(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}-3-methyl-L-valyl-N-(2-aminoethyl)-L-alaninamide × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
pH 5.4；pH 5.4
|
分辨率 2.00 Å R-free 0.270 |
| 1BKC CATALYTIC DOMAIN OF TNF-ALPHA CONVERTING ENZYME (TACE) 提交 1998-04-23 | Assembly 4 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 I
219–474（256 aa）
|
突变：S266A, N452Q | ZN ZINC ION × 1 INN N-{(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}-3-methyl-L-valyl-N-(2-aminoethyl)-L-alaninamide × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
pH 5.4；pH 5.4
|
分辨率 2.00 Å R-free 0.270 |
| 1ZXC Crystal structure of catalytic domain of TNF-alpha converting enzyme (TACE) with inhibitor 提交 2005-06-07 | Assembly 1 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 A
215–477（263 aa）
|
突变：yes | ZN ZINC ION × 1 IH6 (3S)-4-{[4-(BUT-2-YNYLOXY)PHENYL]SULFONYL}-N-HYDROXY-2,2-DIMETHYLTHIOMORPHOLINE-3-CARBOXAMIDE × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 5.4；292 K；PEG 4000, isopropanol, NaCitrate, pH 5.4, VAPOR DIFFUSION, SITTING DROP, temperature 292K
|
分辨率 2.28 Å R-free 0.285 |
| 1ZXC Crystal structure of catalytic domain of TNF-alpha converting enzyme (TACE) with inhibitor 提交 2005-06-07 | Assembly 2 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 B
215–477（263 aa）
|
突变：yes | ZN ZINC ION × 1 IH6 (3S)-4-{[4-(BUT-2-YNYLOXY)PHENYL]SULFONYL}-N-HYDROXY-2,2-DIMETHYLTHIOMORPHOLINE-3-CARBOXAMIDE × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 5.4；292 K；PEG 4000, isopropanol, NaCitrate, pH 5.4, VAPOR DIFFUSION, SITTING DROP, temperature 292K
|
分辨率 2.28 Å R-free 0.285 |
| 2A8H Crystal structure of catalytic domain of TACE with Thiomorpholine Sulfonamide Hydroxamate inhibitor 提交 2005-07-08 | Assembly 1 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 A
215–477（263 aa）
片段：catalytic domain
|
突变：S266A, N452Q | ZN ZINC ION × 1 4NH 4-({4-[(4-AMINOBUT-2-YNYL)OXY]PHENYL}SULFONYL)-N-HYDROXY-2,2-DIMETHYLTHIOMORPHOLINE-3-CARBOXAMIDE × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 5.4；292 K；PEG 4000, isopropanol, NaCitrate, pH 5.4, VAPOR DIFFUSION, SITTING DROP, temperature 292K
|
分辨率 2.30 Å R-free 0.281 |
| 2A8H Crystal structure of catalytic domain of TACE with Thiomorpholine Sulfonamide Hydroxamate inhibitor 提交 2005-07-08 | Assembly 2 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 B
215–477（263 aa）
片段：catalytic domain
|
突变：S266A, N452Q | ZN ZINC ION × 1 4NH 4-({4-[(4-AMINOBUT-2-YNYL)OXY]PHENYL}SULFONYL)-N-HYDROXY-2,2-DIMETHYLTHIOMORPHOLINE-3-CARBOXAMIDE × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 5.4；292 K；PEG 4000, isopropanol, NaCitrate, pH 5.4, VAPOR DIFFUSION, SITTING DROP, temperature 292K
|
分辨率 2.30 Å R-free 0.281 |
| 2DDF Crystal structure of TACE in complex with TAPI-2 提交 2006-01-28 | Assembly 1 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 A
218–474（257 aa）
|
突变：S266A, V353G, Q452N | ZN ZINC ION × 1 CA CALCIUM ION × 1 INN N-{(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}-3-methyl-L-valyl-N-(2-aminoethyl)-L-alaninamide × 1 IPA ISOPROPYL ALCOHOL × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP；pH 5.6；295 K；15% PEG 6K, 10% 2-PROPANOL, 100 MM
SODIUM CITRATE BUFFER , pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
分辨率 1.70 Å R-free 0.230 |
| 2DDF Crystal structure of TACE in complex with TAPI-2 提交 2006-01-28 | Assembly 2 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 B
218–474（257 aa）
|
突变：S266A, V353G, Q452N | ZN ZINC ION × 1 INN N-{(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}-3-methyl-L-valyl-N-(2-aminoethyl)-L-alaninamide × 1 IPA ISOPROPYL ALCOHOL × 3 IMD IMIDAZOLE × 1 CIT CITRIC ACID × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP；pH 5.6；295 K；15% PEG 6K, 10% 2-PROPANOL, 100 MM
SODIUM CITRATE BUFFER , pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
分辨率 1.70 Å R-free 0.230 |
| 2FV5 Crystal structure of TACE in complex with IK682 提交 2006-01-30 | Assembly 1 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 A
216–475（260 aa）
|
突变：S266A, V353G, Q452N | ZN ZINC ION × 1 541 (2R)-N-HYDROXY-2-[(3S)-3-METHYL-3-{4-[(2-METHYLQUINOLIN-4-YL)METHOXY]PHENYL}-2-OXOPYRROLIDIN-1-YL]PROPANAMIDE × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP；pH 5.6；295 K；15% PEG 6K, 10% 2-Propanol, 100 mM sodium citrate buffer, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
分辨率 2.10 Å R-free 0.256 |
| 2FV5 Crystal structure of TACE in complex with IK682 提交 2006-01-30 | Assembly 2 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 B
216–475（260 aa）
|
突变：S266A, V353G, Q452N | ZN ZINC ION × 1 541 (2R)-N-HYDROXY-2-[(3S)-3-METHYL-3-{4-[(2-METHYLQUINOLIN-4-YL)METHOXY]PHENYL}-2-OXOPYRROLIDIN-1-YL]PROPANAMIDE × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP；pH 5.6；295 K；15% PEG 6K, 10% 2-Propanol, 100 mM sodium citrate buffer, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
分辨率 2.10 Å R-free 0.256 |
| 2FV9 Crystal structure of TACE in complex with JMV 390-1 提交 2006-01-30 | Assembly 1 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 A
218–475（258 aa）
|
突变：S266A, V353G, Q452N | ZN ZINC ION × 1 INN N-{(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}-3-methyl-L-valyl-N-(2-aminoethyl)-L-alaninamide × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION；pH 5.6；295 K；15% PEG 6k, 10% 2-Propanol, 100 mM sodium citrate, pH 5.6, VAPOR DIFFUSION, temperature 295K
|
分辨率 2.02 Å R-free 0.264 |
| 2FV9 Crystal structure of TACE in complex with JMV 390-1 提交 2006-01-30 | Assembly 2 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 B
218–475（258 aa）
|
突变：S266A, V353G, Q452N | ZN ZINC ION × 1 002 N-[(2R)-2-BENZYL-4-(HYDROXYAMINO)-4-OXOBUTANOYL]-L-ISOLEUCYL-L-LEUCINE × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION；pH 5.6；295 K；15% PEG 6k, 10% 2-Propanol, 100 mM sodium citrate, pH 5.6, VAPOR DIFFUSION, temperature 295K
|
分辨率 2.02 Å R-free 0.264 |
| 2I47 Crystal structure of catalytic domain of TACE with inhibitor 提交 2006-08-21 | Assembly 1 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 A
212–492（281 aa）
片段：catalytic domain
|
突变：S266A, N452Q | ZN ZINC ION × 1 INN N-{(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}-3-methyl-L-valyl-N-(2-aminoethyl)-L-alaninamide × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 5.4；292 K；20% PEG4000, 20% isopropanol, 0.1M sodium Citrate, pH 5.4, VAPOR DIFFUSION, SITTING DROP, temperature 292K
|
分辨率 1.90 Å R-free 0.227 |
| 2I47 Crystal structure of catalytic domain of TACE with inhibitor 提交 2006-08-21 | Assembly 2 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 B
212–492（281 aa）
片段：catalytic domain
|
突变：S266A, N452Q | ZN ZINC ION × 1 INN N-{(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}-3-methyl-L-valyl-N-(2-aminoethyl)-L-alaninamide × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 5.4；292 K；20% PEG4000, 20% isopropanol, 0.1M sodium Citrate, pH 5.4, VAPOR DIFFUSION, SITTING DROP, temperature 292K
|
分辨率 1.90 Å R-free 0.227 |
| 2I47 Crystal structure of catalytic domain of TACE with inhibitor 提交 2006-08-21 | Assembly 3 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 C
212–492（281 aa）
片段：catalytic domain
|
突变：S266A, N452Q | ZN ZINC ION × 1 KGY 4-({[4-(BUT-2-YN-1-YLOXY)PHENYL]SULFONYL}METHYL)-1-[(3,5-DIMETHYLISOXAZOL-4-YL)SULFONYL]-N-HYDROXYPIPERIDINE-4-CARBOXAMIDE × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 5.4；292 K；20% PEG4000, 20% isopropanol, 0.1M sodium Citrate, pH 5.4, VAPOR DIFFUSION, SITTING DROP, temperature 292K
|
分辨率 1.90 Å R-free 0.227 |
| 2I47 Crystal structure of catalytic domain of TACE with inhibitor 提交 2006-08-21 | Assembly 4 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 D
212–492（281 aa）
片段：catalytic domain
|
突变：S266A, N452Q | ZN ZINC ION × 1 KGY 4-({[4-(BUT-2-YN-1-YLOXY)PHENYL]SULFONYL}METHYL)-1-[(3,5-DIMETHYLISOXAZOL-4-YL)SULFONYL]-N-HYDROXYPIPERIDINE-4-CARBOXAMIDE × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 5.4；292 K；20% PEG4000, 20% isopropanol, 0.1M sodium Citrate, pH 5.4, VAPOR DIFFUSION, SITTING DROP, temperature 292K
|
分辨率 1.90 Å R-free 0.227 |
| 2M2F The membran-proximal domain of ADAM17 提交 2012-12-20 | Assembly 1 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 A
581–642（62 aa）
片段：UNP residues 581-642
|
未记录 | 未记录非水小分子 | SOLUTION NMR |
NMR测量条件
pH 7.4；300 K；离子强度（mmCIF原始值）0.15；压力 ambient
NMR样品组成
1.0 mM [U-100% 13C; U-100% 15N] protein, 90% H2O/10% D2O | 90% H2O/10% D2O
|
分辨率未提供 |
| 2OI0 Crystal structure analysis 0f the TNF-a Coverting Enzyme (TACE) in complexed with Aryl-sulfonamide 提交 2007-01-10 | Assembly 1 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 A
216–477（262 aa）
片段：TACE Proteinase domain (Residues 216-477)
|
突变：S266A, N452Q | ZN ZINC ION × 1 283 (3S)-1-{[4-(BUT-2-YN-1-YLOXY)PHENYL]SULFONYL}PYRROLIDINE-3-THIOL × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；30% PGME 550, 0.1M BIS-TRIS, 50 mM CaCl2, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
|
分辨率 2.00 Å R-free 0.268 |
| 3B92 Novel thio-based TACE inhibitors Part 2: Rational design, synthesis and SAR of thiol-contaning aryl sufones 提交 2007-11-02 | Assembly 1 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 A
216–474（259 aa）
片段：TACE proteinase domain, UNP residues 216-474
|
突变：S266A, N452Q | ZN ZINC ION × 2 440 3-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}propane-1-thiol × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；30% PEGMME 550, 0.1M BIS-TRIS, 50mM CaCl2, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
分辨率 2.00 Å R-free 0.280 |
| 3CKI Crystal structure of the TACE-N-TIMP-3 complex 提交 2008-03-15 | Assembly 1 蛋白异源复合物 异源复合物；蛋白 × 2 PDB 声明：dimeric（2） 与蛋白数一致 |
链 A
219–474（256 aa）
片段：TACE catalytic domain (UNP RESIDUES 219-474)
|
突变：S266A, N452Q | ZN ZINC ION × 1 NA SODIUM ION × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
pH 4.5；309 K；100 mM sodium acetate/acetic acid, 25% polyethylene glycol 3,350, pH 4.5, VAPOR DIFFUSION, SITTING DROP, temperature 309K
|
分辨率 2.30 Å R-free 0.284 |
| 3E8R Crystal structure of catalytic domain of TACE with hydroxamate inhibitor 提交 2008-08-20 | Assembly 1 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 A
215–477（263 aa）
片段：catalytic domain, UNP residues 215-477
|
突变：S266A, V353G, Q452N | ZN ZINC ION × 1 615 (1R,2S)-N~2~-hydroxy-1-{4-[(2-phenylquinolin-4-yl)methoxy]benzyl}cyclopropane-1,2-dicarboxamide × 1 INN N-{(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}-3-methyl-L-valyl-N-(2-aminoethyl)-L-alaninamide × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP；pH 5.6；295 K；15% PEG 6000, 10% 2-Propanol, 100mM sodium citrate buffer, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
分辨率 1.90 Å R-free 0.226 |
| 3E8R Crystal structure of catalytic domain of TACE with hydroxamate inhibitor 提交 2008-08-20 | Assembly 2 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 B
215–477（263 aa）
片段：catalytic domain, UNP residues 215-477
|
突变：S266A, V353G, Q452N | ZN ZINC ION × 1 615 (1R,2S)-N~2~-hydroxy-1-{4-[(2-phenylquinolin-4-yl)methoxy]benzyl}cyclopropane-1,2-dicarboxamide × 1 CIT CITRIC ACID × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP；pH 5.6；295 K；15% PEG 6000, 10% 2-Propanol, 100mM sodium citrate buffer, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
分辨率 1.90 Å R-free 0.226 |
| 3EDZ Crystal structure of catalytic domain of TACE with hydroxamate inhibitor 提交 2008-09-03 | Assembly 1 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 A
215–477（263 aa）
片段：UNP residues 215-477
|
突变：S266A, V353G, N452Q | ZN ZINC ION × 1 INN N-{(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}-3-methyl-L-valyl-N-(2-aminoethyl)-L-alaninamide × 1 CIT CITRIC ACID × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP；pH 5.6；295 K；15% PEG 6000, 10% 2-Propanol, 100 mM sodium citrate buffer, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
分辨率 1.90 Å R-free 0.204 |
| 3EDZ Crystal structure of catalytic domain of TACE with hydroxamate inhibitor 提交 2008-09-03 | Assembly 2 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 B
215–477（263 aa）
片段：UNP residues 215-477
|
突变：S266A, V353G, N452Q | ZN ZINC ION × 1 CIT CITRIC ACID × 1 550 methyl (1R,2S)-2-(hydroxycarbamoyl)-1-{4-[(2-methylquinolin-4-yl)methoxy]benzyl}cyclopropanecarboxylate × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP；pH 5.6；295 K；15% PEG 6000, 10% 2-Propanol, 100 mM sodium citrate buffer, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
分辨率 1.90 Å R-free 0.204 |
| 3EWJ Crystal structure of catalytic domain of TACE with carboxylate inhibitor 提交 2008-10-15 | Assembly 1 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 A
215–477（263 aa）
片段：catalytic domain, UNP residues 215-477
|
突变：S266A, V353G, Q452N | ZN ZINC ION × 1 INN N-{(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}-3-methyl-L-valyl-N-(2-aminoethyl)-L-alaninamide × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP；pH 5.6；295 K；15% PEG 6000, 10% 2-Propanol, 100 mM sodium citrate, pH 5.6, VAPOR DIFFUSION, temperature 295K, VAPOR DIFFUSION, HANGING DROP
|
分辨率 1.80 Å R-free 0.210 |
| 3EWJ Crystal structure of catalytic domain of TACE with carboxylate inhibitor 提交 2008-10-15 | Assembly 2 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 B
215–477（263 aa）
片段：catalytic domain, UNP residues 215-477
|
突变：S266A, V353G, Q452N | ZN ZINC ION × 1 642 (1S,3R,6S)-4-oxo-6-{4-[(2-phenylquinolin-4-yl)methoxy]phenyl}-5-azaspiro[2.4]heptane-1-carboxylic acid × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP；pH 5.6；295 K；15% PEG 6000, 10% 2-Propanol, 100 mM sodium citrate, pH 5.6, VAPOR DIFFUSION, temperature 295K, VAPOR DIFFUSION, HANGING DROP
|
分辨率 1.80 Å R-free 0.210 |
| 3G42 Crystal Structure of TACE with Tryptophan Sulfonamide Derivative Inhibitor 提交 2009-02-03 | Assembly 1 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 A
212–492（281 aa）
片段：catalytic domain
|
突变：S266A, N452Q | 792 N-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}-5-methyl-D-tryptophan × 1 ZN ZINC ION × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 5.4；292 K；PEG4k, isopropanol, NaCitrate, pH 5.4, VAPOR DIFFUSION, SITTING DROP, temperature 292K
|
分辨率 2.10 Å R-free 0.257 |
| 3G42 Crystal Structure of TACE with Tryptophan Sulfonamide Derivative Inhibitor 提交 2009-02-03 | Assembly 2 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 B
212–492（281 aa）
片段：catalytic domain
|
突变：S266A, N452Q | 792 N-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}-5-methyl-D-tryptophan × 1 ZN ZINC ION × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 5.4；292 K；PEG4k, isopropanol, NaCitrate, pH 5.4, VAPOR DIFFUSION, SITTING DROP, temperature 292K
|
分辨率 2.10 Å R-free 0.257 |
| 3G42 Crystal Structure of TACE with Tryptophan Sulfonamide Derivative Inhibitor 提交 2009-02-03 | Assembly 3 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 C
212–492（281 aa）
片段：catalytic domain
|
突变：S266A, N452Q | 792 N-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}-5-methyl-D-tryptophan × 1 ZN ZINC ION × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 5.4；292 K；PEG4k, isopropanol, NaCitrate, pH 5.4, VAPOR DIFFUSION, SITTING DROP, temperature 292K
|
分辨率 2.10 Å R-free 0.257 |
| 3G42 Crystal Structure of TACE with Tryptophan Sulfonamide Derivative Inhibitor 提交 2009-02-03 | Assembly 4 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 D
212–492（281 aa）
片段：catalytic domain
|
突变：S266A, N452Q | 792 N-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}-5-methyl-D-tryptophan × 1 ZN ZINC ION × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 5.4；292 K；PEG4k, isopropanol, NaCitrate, pH 5.4, VAPOR DIFFUSION, SITTING DROP, temperature 292K
|
分辨率 2.10 Å R-free 0.257 |
| 3KMC Crystal structure of catalytic domain of TACE with tartrate-based inhibitor 提交 2009-11-10 | Assembly 1 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 A
215–476（262 aa）
片段：residues 215-476
|
突变：S266A, V353G, Q452N | ZN ZINC ION × 1 INN N-{(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}-3-methyl-L-valyl-N-(2-aminoethyl)-L-alaninamide × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION；pH 5.6；295 K；15% PEG 6000, 10% 2-Propanol, 100 mM sodium citrate, pH 5.6, VAPOR DIFFUSION, temperature 295K
|
分辨率 1.80 Å R-free 0.259 |
| 3KMC Crystal structure of catalytic domain of TACE with tartrate-based inhibitor 提交 2009-11-10 | Assembly 2 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 B
215–476（262 aa）
片段：residues 215-476
|
突变：S266A, V353G, Q452N | ZN ZINC ION × 1 403 (2R,3R)-4-[4-(2-chlorophenyl)piperazin-1-yl]-2,3-dihydroxy-4-oxo-N-(2-thiophen-2-ylethyl)butanamide × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION；pH 5.6；295 K；15% PEG 6000, 10% 2-Propanol, 100 mM sodium citrate, pH 5.6, VAPOR DIFFUSION, temperature 295K
|
分辨率 1.80 Å R-free 0.259 |
| 3KME Crystal structure of catalytic domain of TACE with phenyl-pyrrolidinyl-tartrate inhibitor 提交 2009-11-10 | Assembly 1 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 A
215–476（262 aa）
片段：residues 215-476
|
突变：S266A, V353G, Q452N | ZN ZINC ION × 1 INN N-{(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}-3-methyl-L-valyl-N-(2-aminoethyl)-L-alaninamide × 1 IPA ISOPROPYL ALCOHOL × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION；pH 5.6；295 K；15% PEG 6000, 10% 2-Propanol, 100 mM sodium citrate, pH 5.6, VAPOR DIFFUSION, temperature 295K
|
分辨率 1.85 Å R-free 0.225 |
| 3KME Crystal structure of catalytic domain of TACE with phenyl-pyrrolidinyl-tartrate inhibitor 提交 2009-11-10 | Assembly 2 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 B
215–476（262 aa）
片段：residues 215-476
|
突变：S266A, V353G, Q452N | ZN ZINC ION × 1 Z59 (2R,3R)-2,3-dihydroxy-4-oxo-4-[(2R)-2-phenylpyrrolidin-1-yl]-N-(thiophen-2-ylmethyl)butanamide × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION；pH 5.6；295 K；15% PEG 6000, 10% 2-Propanol, 100 mM sodium citrate, pH 5.6, VAPOR DIFFUSION, temperature 295K
|
分辨率 1.85 Å R-free 0.225 |
| 3L0T Crystal structure of catalytic domain of TACE with hydantoin inhibitor 提交 2009-12-10 | Assembly 1 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 A
215–476（262 aa）
片段：residues 215-476
|
突变：S266A, V353G, N452Q | ZN ZINC ION × 1 INN N-{(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}-3-methyl-L-valyl-N-(2-aminoethyl)-L-alaninamide × 1 IPA ISOPROPYL ALCOHOL × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP；pH 5.6；295 K；15% PEG 6k, 10% 2-Propanol, 100 mM sodium citrate, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
分辨率 1.92 Å R-free 0.239 |
| 3L0T Crystal structure of catalytic domain of TACE with hydantoin inhibitor 提交 2009-12-10 | Assembly 2 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 B
215–476（262 aa）
片段：residues 215-476
|
突变：S266A, V353G, N452Q | ZN ZINC ION × 1 IPA ISOPROPYL ALCOHOL × 1 Z94 N-{4-[(4S)-2,5-dioxoimidazolidin-4-yl]phenyl}acetamide × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP；pH 5.6；295 K；15% PEG 6k, 10% 2-Propanol, 100 mM sodium citrate, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
分辨率 1.92 Å R-free 0.239 |
| 3L0V Crystal structure of catalytic domain of TACE with the first hydantoin inhibitor occupying the S1' pocket 提交 2009-12-10 | Assembly 1 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 A
215–476（262 aa）
片段：residues 215-476
|
突变：S266A, V353G, N452Q | ZN ZINC ION × 1 724 (5R)-5-[(5-methoxy-3-oxo-1,3-dihydro-2H-indazol-2-yl)methyl]-5-methylimidazolidine-2,4-dione × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP；pH 5.6；295 K；15% PEG 6k, 10% 2-Propanol, 100 mM sodium citrate, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
分辨率 1.75 Å R-free 0.208 |
| 3L0V Crystal structure of catalytic domain of TACE with the first hydantoin inhibitor occupying the S1' pocket 提交 2009-12-10 | Assembly 2 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 B
215–476（262 aa）
片段：residues 215-476
|
突变：S266A, V353G, N452Q | ZN ZINC ION × 1 724 (5R)-5-[(5-methoxy-3-oxo-1,3-dihydro-2H-indazol-2-yl)methyl]-5-methylimidazolidine-2,4-dione × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP；pH 5.6；295 K；15% PEG 6k, 10% 2-Propanol, 100 mM sodium citrate, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
分辨率 1.75 Å R-free 0.208 |
| 3LE9 Crystal structure of the catalytic domain of TACE with Indazolinone-phenyl-hydantoin inhibitor 提交 2010-01-14 | Assembly 1 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 A
215–476（262 aa）
片段：residues 215-476
|
突变：S266A, V353G, N452Q | ZN ZINC ION × 1 727 (5R)-5-[(5-methoxy-3-oxo-1,3-dihydro-2H-indazol-2-yl)methyl]-5-phenylimidazolidine-2,4-dione × 1 IPA ISOPROPYL ALCOHOL × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP；pH 5.6；295 K；15% PEG 6K, 10% 2-PROPANOL, 100 MM SODIUM CITRATE, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
分辨率 1.85 Å R-free 0.230 |
| 3LE9 Crystal structure of the catalytic domain of TACE with Indazolinone-phenyl-hydantoin inhibitor 提交 2010-01-14 | Assembly 2 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 B
215–476（262 aa）
片段：residues 215-476
|
突变：S266A, V353G, N452Q | ZN ZINC ION × 1 727 (5R)-5-[(5-methoxy-3-oxo-1,3-dihydro-2H-indazol-2-yl)methyl]-5-phenylimidazolidine-2,4-dione × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP；pH 5.6；295 K；15% PEG 6K, 10% 2-PROPANOL, 100 MM SODIUM CITRATE, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
分辨率 1.85 Å R-free 0.230 |
| 3LEA Crystal structure of the catalytic domain of TACE with Isoindolinone-biphenyl-hydantoin inhibitor 提交 2010-01-14 | Assembly 1 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 A
215–476（262 aa）
片段：residues 215-476
|
突变：S266A, V353G, N452Q | Z93 2-{[(4R)-2,5-dioxo-4-(4-pyridin-3-ylphenyl)imidazolidin-4-yl]methyl}-6-methoxy-1-oxo-1H-isoindolium × 1 ZN ZINC ION × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP；pH 5.6；295 K；15% PEG 6K, 10% 2-PROPANOL, 100 MM SODIUM ACETATE, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
分辨率 2.00 Å R-free 0.219 |
| 3LEA Crystal structure of the catalytic domain of TACE with Isoindolinone-biphenyl-hydantoin inhibitor 提交 2010-01-14 | Assembly 2 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 B
215–476（262 aa）
片段：residues 215-476
|
突变：S266A, V353G, N452Q | Z93 2-{[(4R)-2,5-dioxo-4-(4-pyridin-3-ylphenyl)imidazolidin-4-yl]methyl}-6-methoxy-1-oxo-1H-isoindolium × 1 ZN ZINC ION × 1 IPA ISOPROPYL ALCOHOL × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP；pH 5.6；295 K；15% PEG 6K, 10% 2-PROPANOL, 100 MM SODIUM ACETATE, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
分辨率 2.00 Å R-free 0.219 |
| 3LGP Crystal structure of catalytic domain of tace with benzimidazolyl-thienyl-tartrate based inhibitor 提交 2010-01-21 | Assembly 1 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 A
215–476（262 aa）
|
突变：S266A, V353G, N452Q | ZN ZINC ION × 1 50X (2R,3R)-4-[(2R)-2-(3-chlorophenyl)pyrrolidin-1-yl]-2,3-dihydroxy-4-oxo-N-[(5-{[2-(trifluoromethyl)-1H-benzimidazol-1-yl]methyl}thiophen-2-yl)methyl]butanamide × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP；pH 5.6；295 K；15% PEG 6K, 10% 2-PROPANOL, 100 MM SODIUM ACETATE, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
分辨率 1.90 Å R-free 0.244 |
| 3LGP Crystal structure of catalytic domain of tace with benzimidazolyl-thienyl-tartrate based inhibitor 提交 2010-01-21 | Assembly 2 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 B
215–476（262 aa）
|
突变：S266A, V353G, N452Q | ZN ZINC ION × 1 50X (2R,3R)-4-[(2R)-2-(3-chlorophenyl)pyrrolidin-1-yl]-2,3-dihydroxy-4-oxo-N-[(5-{[2-(trifluoromethyl)-1H-benzimidazol-1-yl]methyl}thiophen-2-yl)methyl]butanamide × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP；pH 5.6；295 K；15% PEG 6K, 10% 2-PROPANOL, 100 MM SODIUM ACETATE, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
分辨率 1.90 Å R-free 0.244 |
| 3O64 Crystal structure of catalytic domain of TACE with 2-(2-Aminothiazol-4-yl)pyrrolidine-Based Tartrate Diamides 提交 2010-07-28 | Assembly 1 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 A
215–476（262 aa）
片段：TACE
|
突变：S266A, V353G, N452Q | IPA ISOPROPYL ALCOHOL × 1 INN N-{(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}-3-methyl-L-valyl-N-(2-aminoethyl)-L-alaninamide × 1 ZN ZINC ION × 1 CA CALCIUM ION × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION；pH 5.6；295 K；15% PEG 6K, 10% 2-Propanol, 100mM Sodium citrate buffer, pH 5.6, VAPOR DIFFUSION, temperature 295K
|
分辨率 1.88 Å R-free 0.218 |
| 3O64 Crystal structure of catalytic domain of TACE with 2-(2-Aminothiazol-4-yl)pyrrolidine-Based Tartrate Diamides 提交 2010-07-28 | Assembly 2 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 B
215–476（262 aa）
片段：TACE
|
突变：S266A, V353G, N452Q | IPA ISOPROPYL ALCOHOL × 4 ZN ZINC ION × 1 786 (2R,3R)-2,3-dihydroxy-4-{(2R)-2-[2-(methylamino)-5-(methylsulfonyl)-1,3-thiazol-4-yl]pyrrolidin-1-yl}-4-oxo-N-{(1R)-1-[4-(1H-pyrazol-1-yl)phenyl]ethyl}butanamide × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION；pH 5.6；295 K；15% PEG 6K, 10% 2-Propanol, 100mM Sodium citrate buffer, pH 5.6, VAPOR DIFFUSION, temperature 295K
|
分辨率 1.88 Å R-free 0.218 |
| 8CQY Crystal structure of the PTPN3 PDZ domain bound to the PBM TACE C-terminal peptide 提交 2023-03-07 | Assembly 1 蛋白异源复合物 异源复合物；蛋白 × 2 PDB 声明：dimeric（2） 与蛋白数一致 |
链 B
813–824（12 aa）
|
未记录 | NA SODIUM ION × 2 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；277.15 K；20% w/v PEG 3350, 0.2 M NaSCN at pH 7
|
分辨率 1.70 Å R-free 0.203 |
| 8SNL Structure of human ADAM17/iRhom2 sheddase complex 提交 2023-04-27 | Assembly 1 蛋白异源复合物 异源复合物；蛋白 × 2 PDB 声明：dimeric（2） 与蛋白数一致 |
链 A
1–824（824 aa）
|
未记录 | ZN ZINC ION × 1 CA CALCIUM ION × 1 | ELECTRON MICROSCOPY |
cryo-EM缓冲液
pH 8
cryo-EM玻璃化条件
冷冻剂 ETHANE
|
分辨率 2.78 Å |
| 8SNM Structure of mature human ADAM17/iRhom2 sheddase complex in complex with ADAM17 prodomain 提交 2023-04-27 | Assembly 1 蛋白异源复合物 异源复合物；蛋白 × 3 PDB 声明：trimeric（3） 与蛋白数一致 |
链 A
1–214（214 aa）
链 B
215–824（610 aa）
|
未记录 | ZN ZINC ION × 1 CA CALCIUM ION × 1 | ELECTRON MICROSCOPY |
cryo-EM缓冲液
pH 8
cryo-EM玻璃化条件
冷冻剂 ETHANE
|
分辨率 3.84 Å |
| 8SNN Structure of mature human ADAM17/iRhom2 sheddase complex, conformation 1 提交 2023-04-27 | Assembly 1 蛋白异源复合物 异源复合物；蛋白 × 2 PDB 声明：dimeric（2） 与蛋白数一致 |
链 A
215–824（610 aa）
|
未记录 | CA CALCIUM ION × 1 | ELECTRON MICROSCOPY |
cryo-EM缓冲液
pH 8
cryo-EM玻璃化条件
冷冻剂 ETHANE
|
分辨率 2.32 Å |
| 8SNO Structure of mature human ADAM17/iRhom2 sheddase complex, conformation 2 提交 2023-04-27 | Assembly 1 蛋白异源复合物 异源复合物；蛋白 × 2 PDB 声明：dimeric（2） 与蛋白数一致 |
链 A
215–824（610 aa）
|
未记录 | CA CALCIUM ION × 1 | ELECTRON MICROSCOPY |
cryo-EM缓冲液
pH 8
cryo-EM玻璃化条件
冷冻剂 ETHANE
|
分辨率 2.78 Å |
| 9E6K Fully human monoclonal antibody targeting the cysteine-rich substrate-interacting region of ADAM17 on cancer cells. 提交 2024-10-30 | Assembly 1 蛋白异源复合物 异源复合物；蛋白 × 3 PDB 声明：trimeric（3） 与蛋白数一致 |
链 C
530–644（115 aa）
|
未记录 | 未记录非水小分子 | ELECTRON MICROSCOPY |
cryo-EM缓冲液
pH 7.4
cryo-EM玻璃化条件
冷冻剂 NITROGEN
|
分辨率 3.15 Å |
| 9O54 ADAM17 Prodomain-Metalloproteinase Domains bound to MEDI3622 Fab 提交 2025-04-09 | Assembly 1 蛋白异源复合物 异源复合物；蛋白 × 3 PDB 声明：trimeric（3） 与蛋白数一致 |
链 A
1–477（477 aa）
|
未记录 | ZN ZINC ION × 1 | ELECTRON MICROSCOPY |
cryo-EM缓冲液
pH 8
cryo-EM玻璃化条件
冷冻剂 ETHANE
|
分辨率 3.50 Å |
| 9O58 Zymogen ADAM17-iRhom2 complex bound by the MEDI3622 Fab 提交 2025-04-09 | Assembly 1 信息不足 异源复合物；蛋白 × 4 PDB 声明：tetrameric（4） 与蛋白数一致 |
链 A
28–824（797 aa）
|
未记录 | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 6 CA CALCIUM ION × 1 ZN ZINC ION × 1 | ELECTRON MICROSCOPY |
cryo-EM缓冲液
pH 8
cryo-EM玻璃化条件
冷冻剂 ETHANE
|
分辨率 3.53 Å |
| 9Q7Y Zymogen ADAM17- iRhom1 Cytoplasmic Deletion (365) Complex Bound by the MEDI3622 Fab 提交 2025-08-25 | Assembly 1 其他组合 异源复合物；蛋白 × 4 PDB 声明：tetrameric（4） 与蛋白数一致 |
链 B
28–698（671 aa）
|
未记录 | CA CALCIUM ION × 1 ZN ZINC ION × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 6 | ELECTRON MICROSCOPY |
cryo-EM缓冲液
pH 8
cryo-EM玻璃化条件
冷冻剂 ETHANE
|
分辨率 3.35 Å |
| 9XY4 Zymogen ADAM17- iRhom1 Cytoplasmic Deletion (370) Complex Bound by the MEDI3622 Fab 提交 2025-08-25 | Assembly 1 其他组合 异源复合物；蛋白 × 4 PDB 声明：tetrameric（4） 与蛋白数一致 |
链 B
28–698（671 aa）
|
未记录 | CA CALCIUM ION × 1 ZN ZINC ION × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 6 | ELECTRON MICROSCOPY |
cryo-EM缓冲液
pH 8
cryo-EM玻璃化条件
冷冻剂 ETHANE
|
分辨率 3.12 Å |